Syros Pharmaceuticals, a new startup company based in greater Boston area, raised $30 million funding in April 2013, which was led by ARCH Venture Partners and Flagship Ventures. Syros will use the capital to develop treatments for cancer and other diseases by controlling the switches that regulate gene expression. The WuXi PharmaTech Corporate Venture Fund participated in the funding to help accelerating the discovery and development of these novel gene control medicines.  MORE—>


Related links:

Syros, a Whitehead and Dana-Farber Spinoff, Snags $30M For Cancer (Source: Xconomy)

Syros Pharma snags $30M funding deal to target master switches of cancer genes (Source: FierceBiotech)

Syros Pharmaceuticals Launches with $30 Million Series A Financing (Source:Syros Pharmaceuticals)